具体实施方式
实施例1:LFn编码序列的扩增
使用PCR方法从质粒pAS22-LF(本研究室构建)扩增出炭疽致死因子的保护性抗原结合结构域的编码序列,所用的引物LF5和LFn3-Linker使用DNA合成仪合成,引物LFn5的5’端添加了Nde I的酶切位点,引物LFn3-Linker的5’端添加了BamH I的酶切位点和编码(Gly Gly Gly GlySer)3连接肽的编码序列。
LF5:5’-aaccatatggcgggcggtcatggtgatgta-3’
LFn3-Linker:
5’-aagggatccagagcccccgccaccagagcccccgccaccagagcccccgccacccc-
-gttgatctttaagttcttc-3’
100μl的PCR反应体系中加入1μl的Vent DNA聚合酶(NEB),20μM的LF5和LFn3-Linker各2μl,2.5mM的dNTP加入8μl,10×PCR反应缓冲液加入10μl.PCR的反应条件为:94℃预变性5分钟,94℃变性30秒,51℃退火30秒,72℃延伸30秒,然后回到预变性,共进行25个循环,最后延伸7分钟。通过琼脂糖凝胶电泳分离PCR产物中的目的条带,然后将目的条带切下,纯化。
实施例2:27LFn编码序列的扩增
27LFn是指去除了N端27个氨基酸残基的LFn。使用PCR方法从质粒pAS22-LF(本研究室构建)扩增出炭疽致死因子的保护性抗原结合结构域的编码序列,所用的引物25LFn5和LFn3-Linker使用DNA合成仪合成,引物LFn5的5’端添加了Nde I的酶切位点,引物LFn3-Linker的5’端添加了BamH I的酶切位点和编码(Gly Gly Gly GlySer)3连接肽的编码序列。
27LFn5:5’-aaccatatgcgaaataaaacacaggaagagc-3’
LFn3-Linker:
5’-aagggatccagagcccccgccaccagagcccccgccaccagagcccccgccacccc-
-gttgatctttaagttcttc-3’
100μl的PCR反应体系中加入1μl的Vent DNA聚合酶(NEB),20μM的LF5和LFn3-Linker各2μl,2.5mM的dNTP加入8μl,10×PCR反应缓冲液加入10μl. PCR的反应条件为:94℃预变性5分钟,94℃变性30秒,51℃退火30秒,72℃延伸30秒,然后回到预变性,共进行25个循环,最后延伸7分钟。通过琼脂糖凝胶电泳分离PCR产物中的目的条带,然后将目的条带切下,纯化。
实施例3:EFn编码序列的扩增
使用PCR方法从质粒pAS22-EF(本研究室构建)扩增出炭疽致死因子的保护性抗原结合结构域的编码序列,所用的引物LF5和LFn3-Linker使用DNA合成仪合成,引物LFn5的5’端添加了Nde I的酶切位点,引物LFn3-Linker的5’端添加了Xho I的酶切位点。
EF5:5’-aacggatccatgaatgaacattacactgagagtgatattaaaag-3’
LFn3-Linker:5’-aacctcgagaccttctttcttcaaactttcacttattttc-3’
100μl的PCR反应体系中加入1μl的Vent DNA聚合酶(NEB),20μM的LF5和LFn3-Linker各2μl,2.5mM的dNTP加入8μl,10×PCR反应缓冲液加入10μl.PCR的反应条件为:94℃预变性5分钟,94℃变性30秒,50℃退火30秒,72℃延伸30秒,然后回到预变性,共进行25个循环,最后延伸7分钟。通过琼脂糖凝胶电泳分离PCR产物中的目的条带,然后将目的条带切下,纯化。
实施例4:连接肽为(Gly Gly Gly GlySer)3时LFn/EFn融合蛋白表达载体的构建。
取2μg的LFn的使用实施例1中引物扩增得到的LFn编码序列,设置50μl的双酶切体系,具体如下:2μg的LFn编码序列,5μl的NEB酶切反应缓冲液2,2μl的Nde I和2μl的BamH I,0.5μl的100×BSA,加双蒸水至总体积50μl,37℃水浴中反应10小时。10小时后使用凝胶回收试剂盒(BBI)纯化LFn编码序列的双酶切产物。
取800ng的pET21a(Novagen公司)载体,设置50μl的双酶切体系,具体如下:800ng的pET21a载体,5μl的NEB酶切反应缓冲液2,2μl的Nde I和2μl的BamH I,0.5μl的100×BSA,加双蒸水至总体积50μl,37℃水浴中反应10小时。10小时后使用0.6%的琼脂糖凝胶电泳分离酶切产物,然后将目的条带切下,凝胶回收试剂盒(BBI)纯化pET21a的双酶切产物。
连接反应:取3μl经过纯化的pET21a的Nde I和BamH I双酶切产物,加入5μl经过纯化的LFn的Nde I和BamHI双酶切产物,1μl的T4 DNA连接酶(TaKaRa)和1μl的10×T4 DNA连接酶反应缓冲液,16℃水浴中连接13小时.
连接产物转化大肠杆菌DH5α,然后挑取克隆送公司测序(感受态DH5α的制备方法及转化方法依照“分子克隆实验指南”第二版所述。J.萨姆布鲁克著)。所得重组质粒命名为pE T21a-LFnLinker。
取2μg的使用实施例3中引物扩增得到的EFn编码序列,设置50μl的双酶切体系,具体如下:2μg的EFn编码序列,5μl的NEB酶切反应缓冲液2,2μl的Xho I和2μl的BamH I,0.5μl的100×BSA,加双蒸水至总体积50μl,37℃水浴中反应10小时。10小时后使用0.6%的琼脂糖凝胶电泳分离酶切产物,然后将目的条带切下,凝胶回收试剂盒(BBI)纯化EFn编码序列的双酶切产物。
取800ng的pET21a-LFnLinker载体,设置50μl的双酶切体系,具体如下:800ng的pET21a-LFnLinker载体,5μl的NEB酶切反应缓冲液2,2μl的XhoI和2μl的BamH I,0.5μl的100×BSA,加双蒸水至总体积50μl,37℃水浴中反应10小时。10小时后使用0.6%的琼脂糖凝胶电泳分离酶切产物,然后将目的条带切下,凝胶回收试剂盒(BBI)纯化pET21a-LFnLinker的双酶切产物。
连接反应:取3μl经过纯化的pET21a-LFnLinker的Xho I和BamH I双酶切产物,加入5μl经过纯化的EFn的Xho I和BamH I双酶切产物,1μl的T4 DNA连接酶(TaKaRa)和1μl的10×T4 DNA连接酶反应缓冲液,16℃水浴中连接13小时.
连接产物转化大肠杆菌DH5α,然后挑取克隆送公司测序(感受态DH5α的制备方法及转化方法依照“分子克隆实验指南”第二版所述。J.萨姆布鲁克著)。所得重组质粒命名为pET21a-LFnEFn。
实施例5:连接肽为(Gly Gly Gly GlySer)3时27LFn/EFn融合蛋白表达载体的构建。
取2μg的27LFn的使用实施例2中引物扩增得到的LFn编码序列,设置50μl的双酶切体系,具体如下:2μg的27LFn编码序列,5μl的NEB酶切反应缓冲液2,2μl的Nde I和2μl的BamH I,0.5μl的100×BSA,加双蒸水至总体积50μl,37℃水浴中反应10小时。10小时后使用凝胶回收试剂盒(BBI)纯化LFn编码序列的双酶切产物。
连接反应:取3μl经过纯化的pET21a的Nde I和BamH I双酶切产物(实施例4),加入5μl经过纯化的27LFn的Nde I和BamH I双酶切产物,1μl的T4DNA连接酶(TaKaRa)和1μl的10×T4 DNA连接酶反应缓冲液,16℃水浴中连接13小时.
连接产物转化大肠杆菌Top10,然后挑取克隆送公司测序(感受态Top10的制备方法及转化方法依照“分子克隆实验指南”第二版所述。J.萨姆布鲁克著)。所得重组质粒命名为pET21a-27LFnLinker。
取800ng的pET21a-27LFnLinker载体,设置50μl的双酶切体系,具体如下:800ng的pET21a-27LFnLinker载体,5μl的NEB酶切反应缓冲液2,2μl的Xho I和2μl的BamH I,0.5μl的100×BSA,加双蒸水至总体积50μl,37℃水浴中反应10小时。10小时后使用0.6%的琼脂糖凝胶电泳分离酶切产物,然后将目的条带切下,凝胶回收试剂盒(BBI)纯化pET21a-LFnLinker的双酶切产物。
连接反应:取3μl经过纯化的pET21a-LFnLinker的Xho I和BamH I双酶切产物,加入5μl经过纯化的EFn的Xho I和BamH I双酶切产物(实施例4),1μl的T4 DNA连接酶(TaKaRa)和1μl的10×T4 DNA连接酶反应缓冲液,16℃水浴中连接13小时.
连接产物转化大肠杆菌DH5α,然后挑取克隆送公司测序(感受态DH5α的制备方法及转化方法依照“分子克隆实验指南”第二版所述。J.萨姆布鲁克著)。所得重组质粒命名为pET21a-27LFnEFn。
实施例6:LFn/EFn和27LFn/EFn融合蛋白融合蛋白的表达纯化。
将所获得的pET21a-LFnEFn和pET21a-27LFnEFn质粒转化E.coli BL21(DE3)(Novagen公司)感受态细胞(感受态制备方法同DH5α)。工程菌的诱导表达:挑取克隆于5ml含100μg/ml氨苄青霉素的LB培养基中,在37℃250rpm培养,培养至OD600 0.5~0.7,加入IPTG至终浓度1mmol/L,在28℃250r/m进行诱导表达6h,1000rpm离心5min离心收集菌体沉淀超声(方法及参数依照超声仪制造商的说明)。超声所得菌液12000g,室温离心2min,取上清进行SDS-PAGE分析,以确定重组蛋白是否表达,SDS-PAGE电泳的样品制备方法、电泳电压、凝胶染色和脱色的方法见“分子克隆实验指南”第二版所述。J.萨姆布鲁克著。
取20ml种子液接种入装有1L LB-Amp培养基的3L锥形瓶,37℃培养至OD600为0.6左右,然后加入终浓度为0.5mM的IPTG,将温度降为28℃诱导8h后,8000g离心获得菌体,加入1/10体积的20mmol/L Tris(pH8.0)重悬菌体,然后超声破碎菌体,4℃,12000g离心10min,收集上清。在上清液中添加咪唑和NaCl至终浓度为50mmol/L咪唑,0.5mol/LNaCl。在AKTA-explorer上将上述超声溶液上Ni柱。平衡缓冲液为20mmol/LTris0.5mol/LNaCl 50mmol/L咪唑pH8.0。上样后使用洗脱液(20mmol/L Tris 0.5mol/LNaCl 0.5mol/L咪唑pH8.0)洗脱,收集洗脱峰。纯化蛋白经超滤浓缩,再通过Superdex75凝胶过滤柱进一步纯化,收集蛋白洗脱峰,得到目的蛋白。BCA法测定蛋白浓度。
实施例7:融合蛋白的细胞保护性检测
小鼠巨噬细胞J774A.1以104个/ml接种于96孔细胞培养板,培养约24小时,长至90%满。用含有100ng/ml PA和LF的新鲜培养液对各样品进行2倍系列稀释,然后按顺序加入洁净96孔细胞培养板,每样品2复孔,每孔120μl;后于细胞培养箱中37℃孵育1h。小心地将J774A.1细胞培养上清吸去,将孵育1h的样品转加于含有J774A.1细胞的培养板中,于细胞培养箱中37℃孵育3h后,吸出96孔细胞培养板中的培养液,按100μl/孔加入MTT溶液(终浓度1mg/ml,用培养液配制而成),37℃孵育30min,吸出MTT溶液,每孔加入100μl盐酸-异丙醇,作用10min,用酶联仪测吸光度OD570,结果取平行的3个孔的平均值。结果表明融合蛋白的体外毒素中和能力较LFn和EFn单体有较大的提高。
实施例8:融合蛋白保护F344雄性大鼠免受炭疽致死毒素的攻击。
F344雄性大鼠购自维通利华;PA、LF由本室制备,PA、LF和27LE均使用注射用水进行稀释,每只大鼠注射40μg的PA和10μg的LF。注射体积为500μl。试剂经由尾静脉注入,大鼠连续观察48小时以上。结果显示炭疽致死毒素与重组蛋白27LE以一定的摩尔比同时注入有保护效果,大鼠全部存活(连续观察48小时以上。),当摩尔比低于一定值时,大鼠的生存时间得到延长,但出现了严重的肺部损伤,最终死亡。高摩尔比时,与对照相比大鼠没有出现可见的中毒症状。
表1:同时注射毒素和融合蛋白27LFn/EFn
组别 |
存活数/总数 |
存活时间 |
PA+LF(40ug+10ug) |
0/3 |
65±3min |
PA+LF+8倍摩尔比27LFn/EFn |
0/3 |
272±45min |
PA+LF+16倍摩尔比27LFn/EFn |
3/3 |
48h以上 |
序列表
<110>中国人民解放军军事医学科学院微生物流行病研究所
<120>炭疽致死因子结构域(LFn)与炭疽水肿因子结构域(EFn)的融合蛋白及其应用
<130>
<160>8
<210>1
<211>789
<212>DNA
<213>LFn
<400>1
gcgggcggtc atggtgatgt aggtatgcac gtaaaagaga aagagaaaaa taaagatgag 60
aataagagaa aagatgaaga acgaaataaa acacaggaag agcatttaaa ggaaatcatg 120
aaacacattg taaaaataga agtaaaaggg gaggaagctg ttaaaaaaga ggcagcagaa 180
aagctacttg agaaagtacc atctgatgtt ttagagatgt ataaagcaat tggaggaaag 240
atatatattg tggatggtga tattacaaaa catatatctt tagaagcatt atctgaagat 300
aagaaaaaaa taaaagacat ttatgggaaa gatgctttat tacatgaaca ttatgtatat 360
gcaaaagaag gatatgaacc cgtacttgta atccaatctt cggaagatta tgtagaaaat 420
actgaaaagg cactgaacgt ttattatgaa ataggtaaga tattatcaag ggatatttta 480
agtaaaatta atcaaccata tcagaaattt ttagatgtat taaataccat taaaaatgca 540
tctgattcag atggacaaga tcttttattt actaatcagc ttaaggaaca tcccacagac 600
ttttctgtag aattcttgga acaaaatagc aatgaggtac aagaagtatt tgcgaaagct 660
tttgcatatt atatcgagcc acagcatcgt gatgttttac agctttatgc accggaagct 720
tttaattaca tggataaatt taacgaacaa gaaataaatc tatccttgga agaacttaaa 780
gatcaacgg 789
<210>2
<211>263
<212>PRT
<213>LFn
<400>2
Ala Gly Gly His Gly Asp Val Gly Met His Val Lys Glu Lys Glu
1 5 10 15
Lys Asn Lys Asp Glu Asn Lys Arg Lys Asp Glu Glu Arg Asn Lys
16 20 25 30
Thr Gln Glu Glu His Leu Lys Glu Ile Met Lys His Ile Val Lys
31 35 40 45
Ile Glu Val Lys Gly Glu Glu Ala Val Lys Lys Glu Ala Ala Glu
46 50 55 60
Lys Leu Leu Glu Lys Val Pro Ser Asp Val Leu Glu Met Tyr Lys
61 65 70 75
Ala Ile Gly Gly Lys Ile Tyr Ile Val Asp Gly Asp Ile Thr Lys
76 80 85 90
His Ile Ser Leu Glu Ala Leu Ser Glu Asp Lys Lys Lys Ile Lys
91 95 100 105
Asp Ile Tyr Gly Lys Asp Ala Leu Leu His Glu His Tyr Val Tyr
106 110 115 120
Ala Lys Glu Gly Tyr Glu Pro Val Leu Val Ile Gln Ser Ser Glu
121 125 130 135
Asp Tyr Val Glu Asn Thr Glu Lys Ala Leu Asn Val Tyr Tyr Glu
136 140 145 150
Ile Gly Lys Ile Leu Ser Arg Asp Ile Leu Ser Lys Ile Asn Gln
151 155 160 165
Pro Tyr Gln Lys Phe Leu Asp Val Leu Asn Thr Ile Lys Asn Ala
166 170 175 180
Ser Asp Ser Asp Gly Gln Asp Leu Leu Phe Thr Asn Gln Leu Lys
181 185 190 195
Glu His Pro Thr Asp Phe Ser Val Glu Phe Leu Glu Gln Asn Ser
196 200 205 210
Asn Glu Val Gln Glu Val Phe Ala Lys Ala Phe Ala Tyr Tyr Ile
211 215 220 225
Glu Pro Gln His Arg Asp Val Leu Gln Leu Tyr Ala Pro Glu Ala
226 230 235 240
Phe Asn Tyr Met Asp Lys Phe Asn Glu Gln Glu Ile Asn Leu Ser
241 245 250 255
Leu Glu Glu Leu Lys Asp Gln Arg
256 260 263
<210>3
<211>45
<212>DNA
<213>Linker
<400>1
ggtggcgggg gctctggtgg cgggggctct ggtggcgggg gctct 45
<210>4
<211>15
<212>PRT
<213>Linker
<400>2
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15
<210>5
<211>762
<212>DNA
<213>EFn
<400>1
atgaatgaac attacactga gagtgatatt aaaagaaacc ataaaactga aaaaaataaa 60
actgaaaaag aaaaatttaa agacagtatt aataacttag ttaaaacaga atttaccaat 120
gaaactttag ataaaataca gcagacacaa gacttattaa aaaagatacc taaggatgta 180
cttgaaattt atagtgaatt aggaggagaa atctatttta cagatataga tttagtagaa 240
cataaggagt tacaagattt aagtgaagaa gagaaaaata gtatgaatag tagaggtgaa 300
aaagttccgt ttgcatcccg ttttgtattt gaaaagaaaa gggaaacacc taaattaatt 360
ataaatatca aagattatgc aattaatagt gaacaaagta aagaagtata ttatgaaatt 420
ggaaagggga tttctcttga tattataagt aaggataaat ctctagatcc agagttttta 480
aatttaatta agagtttaag cgatgatagt gatagtagcg accttttatt tagtcaaaaa 540
tttaaagaga agctagaatt gaataataaa agtatagata taaattttat aaaagaaaat 600
ttaactgaat ttcagcatgc gttttcttta gcgttttctt attattttgc acctgaccat 660
agaacggtat tagagttata tgcccccgac atgtttgagt atatgaataa gttagaaaaa 720
gggggatttg agaaaataag tgaaagtttg aagaaagaag gt 762
<210>6
<211>254
<212>PRT
<213>EFn
<400>2
Met Asn Glu His Tyr Thr Glu Ser Asp Ile Lys Arg Asn His Lys
1 5 10 15
Thr Glu Lys Asn Lys Thr Glu Lys Glu Lys Phe Lys Asp Ser Ile
16 20 25 30
Asn Asn Leu Val Lys Thr Glu Phe Thr Asn Glu Thr Leu Asp Lys
31 35 40 45
Ile Gln Gln Thr Gln Asp Leu Leu Lys Lys Ile Pro Lys Asp Val
46 50 55 60
Leu Glu Ile Tyr Ser Glu Leu Gly Gly Glu Ile Tyr Phe Thr Asp
61 65 70 75
Ile Asp Leu Val Glu His Lys Glu Leu Gln Asp Leu Ser Glu Glu
76 80 85 90
Glu Lys Asn Ser Met Asn Ser Arg Gly Glu Lys Val Pro Phe Ala
91 95 100 105
Ser Arg Phe Val Phe Glu Lys Lys Arg Glu Thr Pro Lys Leu Ile
106 110 115 120
lle Asn Ile Lys Asp Tyr Ala Ile Asn Ser Glu Gln Ser Lys Glu
121 125 130 135
Val Tyr Tyr Glu Ile Gly Lys Gly Ile Ser Leu Asp Ile Ile Ser
136 140 145 150
Lys Asp Lys Ser Leu Asp Pro Glu Phe Leu Asn Leu Ile Lys Ser
151 155 160 165
Leu Ser Asp Asp Ser Asp Ser Ser Asp Leu Leu Phe Ser Gln Lys
166 170 175 180
Phe Lys Glu Lys Leu Glu Leu Asn Asn Lys Ser Ile Asp Ile Asn
181 185 190 195
Phe Ile Lys Glu Asn Leu Thr Glu Phe Gln His Ala Phe Ser Leu
196 200 205 210
Ala Phe Ser Tyr Tyr Phe Ala Pro Asp His Arg Thr Val Leu Glu
211 215 220 225
Leu Tyr Ala Pro Asp Met Phe Glu Tyr Met Asn Lys Leu Glu Lys
226 230 235 240
Gly Gly Phe Glu Lys Ile Ser Glu Ser Leu Lys Lys Glu Gly
241 245 250 254
<210>7
<211>1626
<212>DNA
<213>LFn/EFn FUSION PROTEIN
<400>1
gcgggcggtc atggtgatgt aggtatgcac gtaaaagaga aagagaaaaa taaagatgag 60
aataagagaa aagatgaaga acgaaataaa acacaggaag agcatttaaa ggaaatcatg 120
aaacacattg taaaaataga agtaaaaggg gaggaagctg ttaaaaaaga ggcagcagaa 180
aagctacttg agaaagtacc atctgatgtt ttagagatgt ataaagcaat tggaggaaag 240
atatatattg tggatggtga tattacaaaa catatatctt tagaagcatt atctgaagat 300
aagaaaaaaa taaaagacat ttatgggaaa gatgctttat tacatgaaca ttatgtatat 360
gcaaaagaag gatatgaacc cgtacttgta atccaatctt cggaagatta tgtagaaaat 420
actgaaaagg cactgaacgt ttattatgaa ataggtaaga tattatcaag ggatatttta 480
agtaaaatta atcaaccata tcagaaattt ttagatgtat taaataccat taaaaatgca 540
tctgattcag atggacaaga tcttttattt actaatcagc ttaaggaaca tcccacagac 600
ttttctgtag aattcttgga acaaaatagc aatgaggtac aagaagtatt tgcgaaagct 660
tttgcatatt atatcgagcc acagcatcgt gatgttttac agctttatgc accggaagct 720
tttaattaca tggataaatt taacgaacaa gaaataaatc tatccttgga agaacttaaa 780
gatcaacggg gtggcggggg ctctggtggc gggggctctg gtggcggggg ctctggatcc 840
atgaatgaac attacactga gagtgatatt aaaagaaacc ataaaactga aaaaaataaa 900
actgaaaaag aaaaatttaa agacagtatt aataacttag ttaaaacaga atttaccaat 960
gaaactttag ataaaataca gcagacacaa gacttattaa aaaagatacc taaggatgta 1020
cttgaaattt atagtgaatt aggaggagaa atctatttta cagatataga tttagtagaa 1080
cataaggagt tacaagattt aagtgaagaa gagaaaaata gtatgaatag tagaggtgaa 1140
aaagttccgt ttgcatcccg ttttgtattt gaaaagaaaa gggaaacacc taaattaatt 1200
ataaatatca aagattatgc aattaatagt gaacaaagta aagaagtata ttatgaaatt 1260
ggaaagggga tttctcttga tattataagt aaggataaat ctctagatcc agagttttta 1320
aatttaatta agagtttaag cgatgatagt gatagtagcg accttttatt tagtcaaaaa 1380
tttaaagaga agctagaatt gaataataaa agtatagata taaattttat aaaagaaaat 1440
ttaactgaat ttcagcatgc gttttcttta gcgttttctt attattttgc acctgaccat 1500
agaacggtat tagagttata tgcccccgac atgtttgagt atatgaataa gttagaaaaa 1560
gggggatttg agaaaataag tgaaagtttg aagaaagaag gtctcgagca ccaccaccac 1620
caccac 1626
<210>8
<211>542
<212>PRT
<213>LFn/EFn FUSION PROTEIN
<400>2
Ala Gly Gly His Gly Asp Val Gly Met His Val Lys Glu Lys Glu
1 5 10 15
Lys Asn Lys Asp Glu Asn Lys Arg Lys Asp Glu Glu Arg Asn Lys
16 20 25 30
Thr Gln Glu Glu His Leu Lys Glu Ile Met Lys His Ile Val Lys
31 35 40 45
Ile Glu Val Lys Gly Glu Glu Ala Val Lys Lys Glu Ala Ala Glu
46 50 55 60
Lys Leu Leu Glu Lys Val Pro Ser Asp Val Leu Glu Met Tyr Lys
61 65 70 75
Ala Ile Gly Gly Lys Ile Tyr Ile Val Asp Gly Asp Ile Thr Lys
76 80 85 90
His Ile Ser Leu Glu Ala Leu Ser Glu Asp Lys Lys Lys Ile Lys
91 95 100 105
Asp Ile Tyr Gly Lys Asp Ala Leu Leu His Glu His Tyr Val Tyr
106 110 115 120
Ala Lys Glu Gly Tyr Glu Pro Val Leu Val Ile Gln Ser Ser Glu
121 125 130 135
Asp Tyr Val Glu Asn Thr Glu Lys Ala Leu Asn Val Tyr Tyr Glu
136 140 145 150
Ile Gly Lys Ile Leu Ser Arg Asp Ile Leu Ser Lys Ile Asn Gln
151 155 160 165
Pro Tyr Gln Lys Phe Leu Asp Val Leu Asn Thr Ile Lys Asn Ala
166 170 175 180
Ser Asp Ser Asp Gly Gln Asp Leu Leu Phe Thr Asn Gln Leu Lys
181 185 190 195
Glu His Pro Thr Asp Phe Ser Val Glu Phe Leu Glu Gln Asn Ser
196 200 205 210
Asn Glu Val Gln Glu Val Phe Ala Lys Ala Phe Ala Tyr Tyr Ile
211 215 220 225
Glu Pro Gln His Arg Asp Val Leu Gln Leu Tyr Ala Pro Glu Ala
226 230 235 240
Phe Asn Tyr Met Asp Lys Phe Asn Glu Gln Glu Ile Asn Leu Ser
241 245 250 255
Leu Glu Glu Leu Lys Asp Gln Arg Gly Gly Gly Gly Ser Gly Gly
256 260 265 270
Gly Gly Ser Gly Gly Gly Gly Ser Gly Ser Met Asn Glu His Tyr
271 275 280 285
Thr Glu Ser Asp Ile Lys Arg Asn His Lys Thr Glu Lys Asn Lys
286 290 295 300
Thr Glu Lys Glu Lys Phe Lys Asp Ser Ile Asn Asn Leu Val Lys
301 305 310 315
Thr Glu Phe Thr Asn Glu Thr Leu Asp Lys Ile Gln Gln Thr Gln
316 320 325 330
Asp Leu Leu Lys Lys Ile Pro Lys Asp Val Leu Glu Ile Tyr Ser
331 335 340 345
Glu Leu Gly Gly Glu Ile Tyr Phe Thr Asp Ile Asp Leu Val Glu
346 350 355 360
His Lys Glu Leu Gln Asp Leu Ser Glu Glu Glu Lys Asn Ser Met
361 365 370 375
Asn Ser Arg Gly Glu Lys Val Pro Phe Ala Ser Arg Phe Val Phe
376 380 385 390
Glu Lys Lys Arg Glu Thr Pro Lys Leu Ile Ile Asn Ile Lys Asp
391 395 400 405
Tyr Ala Ile Asn Ser Glu Gln Ser Lys Glu Val Tyr Tyr Glu Ile
406 410 415 420
Gly Lys Gly Ile Ser Leu Asp Ile Ile Ser Lys Asp Lys Ser Leu
421 425 430 435
Asp Pro Glu Phe Leu Asn Leu Ile Lys Ser Leu Ser Asp Asp Ser
436 440 445 450
Asp Ser Ser Asp Leu Leu Phe Ser Gln Lys Phe Lys Glu Lys Leu
451 455 456 460
Glu Leu Asn Asn Lys Ser Ile Asp Ile Asn Phe Ile Lys Glu Asn
461 465 470 475
Leu Thr Glu Phe Gln His Ala Phe Ser Leu Ala Phe Ser Tyr Tyr
476 480 485 490
Phe Ala Pro Asp His Arg Thr Val Leu Glu Leu Tyr Ala Pro Asp
491 500 505 510
Met Phe Glu Tyr Met Asn Lys Leu Glu Lys Gly Gly Phe Glu Lys
511 515 520 525
Ile Ser Glu Ser Leu Lys Lys Glu Gly Leu Glu His His His His
526 530 535 540
His His
542